Weight-Loss Plateau on Ozempic, Wegovy or Zepbound: Why It Happens and What the Evidence Says

If you’ve been on semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro) for months and the scale has stopped moving, you’ve most likely reached a plateau: the point where your body and the medication settle into a new balance. That’s expected, not a failure. In an analysis of the SURMOUNT-1 trial, nearly 9 in 10 participants on tirzepatide who had lost at least 5% were on a plateau by week 72. For semaglutide, the EU prescribing information for Wegovy describes a two-year trial in which mean body weight fell through week 68, after which a plateau was reached.

Here I explain why it happens, how to tell it apart from a slow or smaller response, and what has evidence behind it. The numbers on how much people lose are in how much weight people lose on Ozempic, Wegovy or Zepbound. The drug facts come from the US prescribing information for Wegovy, Zepbound and Ozempic. Any change to your dose or treatment is a decision for you and your prescriber.

Why weight stalls: your body adapts

Losing weight changes both sides of the equation: how much energy you burn and how hungry you feel.

You burn less energy. A smaller body burns less, and resting energy use can drop more than that change alone explains. This is called metabolic adaptation. Fothergill and colleagues (2016) followed 14 contestants from a TV weight-loss show who lost an average of 58.3 kg (128.5 lb) in 30 weeks. Six years later, their resting energy use was still 704 kcal a day below where it started, and 499 kcal of that wasn’t explained by changes in their bodies or by age. It’s an extreme, very small case: the numbers don’t carry over to someone on a GLP-1, but the mechanism does.

You get hungrier. This effect is even stronger. Polidori and colleagues (2016) studied 153 people treated for 52 weeks with canagliflozin, a diabetes drug that removes calories through the urine without people noticing. For every kilogram lost, appetite pushed them to eat about 100 kcal a day more than at the start (roughly 45 kcal per pound). That’s more than three times the drop in energy use. And Sumithran and colleagues (2011) found that a year after people lost 13.5 kg (29.8 lb) on a diet, ghrelin (which stimulates hunger) was still higher, and hormones that curb it, such as leptin and peptide YY, were still lower. I explain these signals in the science of satiety.

In short: the drug puts a brake on appetite and your body pushes the other way. When the two forces even out, weight settles at a lower point than where you started. The same happens without medication, just sooner: in the two-year Wegovy trial (STEP 5), the EU prescribing information says that on placebo, mean body weight fell less and reached a plateau after about 20 weeks.

When the plateau shows up in the trials

• Tirzepatide. Horn and colleagues (2025) analyzed 1,438 SURMOUNT-1 participants who stayed on treatment and lost at least 5%. They defined a plateau as losing less than 5% over a 12-week period and in every period after it. The median (the middle value) was 24.3 weeks in people with overweight and 36.1 weeks in people with class II or III obesity. By week 72, between 87.6% and 90.2% were on a plateau. It came later on the 10 and 15 mg doses, in younger people and in women.
• Semaglutide. In STEP 5, with 304 adults over 104 weeks, the EU prescribing information for Wegovy reports that mean body weight fell through week 68 and then plateaued, with a final change of −15.2%. The US label doesn’t include STEP 5.
• Overall. The 2025 joint advisory from four US medical and nutrition societies (I’ll call it “the advisory”) sums it up: with these drugs, weight loss is fastest in the first 6 months and tends to level off at around 18 months.

One nuance: under Horn’s definition, losing slowly, say 2% every three months, already counts as a plateau.

Plateau, slow response or smaller response: not the same thing

“It’s not working,” “I’ve stalled” and “I’m barely losing” describe different situations.

Plateau. You lost weight for months and now it’s holding steady. That alone doesn’t mean the drug has stopped working. Quite the opposite: in withdrawal trials such as SURMOUNT-4, people switched from the drug to placebo regained a good part of the weight.

Slow response at the start. Trials usually define “response” as losing at least 5% of body weight. In Ard and colleagues’ analysis (2025) of 1,545 SURMOUNT-1 participants who took at least 75% of their doses, 18% hadn’t reached 5% by week 12. Of those, 70% got there by week 24 and 90% by week 72. For semaglutide, a STEP 4 conference abstract used week 20 as the cutoff: people who hadn’t reached 5% and stayed on the drug lost an average of 6.4% from the start to week 68, versus 0.3% for those switched to placebo. A slow start doesn’t mean it won’t work.

Smaller response. Some people lose less than expected even after months. The trials link this to factors such as type 2 diabetes, sex and dose, which I go over in how much weight people lose. Whether treatment still makes sense for you is something to weigh with your prescriber.

Gaining weight during treatment isn’t a plateau. It’s worth a doctor’s visit, because it can have other causes (more on that below).

What the US labels say about dosing

This is what the labels say, checked on September 23, 2026:

• Wegovy. It starts at 0.25 mg once a week and is stepped up every 4 weeks over 16 weeks; the maintenance dose for weight reduction in adults is 1.7 mg or 2.4 mg (recommended). For people who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated, the dose may be increased to a maximum of 7.2 mg once weekly. The label asks prescribers to consider treatment response and tolerability when selecting the maintenance dose, and says that if a dose isn’t tolerated during escalation, delaying the next increase for 4 weeks may be considered. The EU prescribing information adds two conditions the US label doesn’t have: 7.2 mg is for adults with a BMI (body mass index) of 30 or more at the start of treatment, and if there’s no additional clinical improvement in body weight on 7.2 mg, the dose goes back to 2.4 mg.
• Zepbound. It starts at 2.5 mg once a week for 4 weeks, then goes to 5 mg; the dose may be increased in 2.5 mg steps after at least 4 weeks on the current one. Maintenance doses for weight reduction are 5, 10 or 15 mg, and the maximum is 15 mg. If a maintenance dose isn’t tolerated, a lower one can be considered.
• Ozempic. It’s indicated for adults with type 2 diabetes; for blood sugar control, the dose goes up to 1 mg and then 2 mg only if additional glycemic control is needed. It isn’t approved for weight management.

These are rules for prescribers, not a schedule to follow on your own. Whether your dose changes or stays the same is your doctor’s decision, based on your progress and your symptoms.

What has evidence when your weight stalls

I haven’t found trials that test strategies for getting past a plateau on a GLP-1. What follows has support for other goals, such as keeping muscle, and it’s what medical societies recommend.

Strength training and protein. The advisory recommends strength training at least three times a week and 150 minutes a week of moderate aerobic activity, mainly to preserve muscle and bone. It notes that 1.2 to 1.6 g of protein per kilogram a day (0.54 to 0.73 g per pound) has been proposed during active weight loss. In Sardeli’s meta-analysis (2018) of six trials in older adults with obesity on calorie-restricted diets, strength training three times a week prevented 93.5% of the loss of lean mass. Fat and weight loss were similar with or without training: strength work didn’t make the scale drop faster, but it changed what was lost. I go deeper in protein and muscle on GLP-1 medications, and you can estimate your number with the protein calculator (in Spanish, in kilograms).

Sleep. According to the advisory, poor sleep is linked to more insulin resistance, more hunger and weight gain, which could cancel out part of these drugs’ benefit.

Alcohol. It has 7 calories per gram, almost as many as fat, according to the NHS. The advisory adds that on a GLP-1 it can make nausea and reflux worse, and advises keeping it to a minimum.

Meal structure. The advisory recommends eating at regular times, even when your appetite is small. My guide to what to eat on GLP-1 medications has ideas for each phase, and the weekly menu planner (in Spanish) can help you organize them.

Tracking, only if it sits well with you. The advisory lists tracking weight, food and activity among the parts of programs for losing and maintaining weight. Writing things down for a few days can help you show up to your appointment with real data. If weighing yourself or counting makes you anxious, drop it and mention it to your doctor or a registered dietitian.

A medical check. According to MedlinePlus, some medicines can cause weight gain (birth control pills, corticosteroids, some medicines for depression, bipolar disorder, schizophrenia or diabetes), and so can conditions such as hypothyroidism, polycystic ovary syndrome or menopause. Hypothyroidism can start with fatigue, feeling cold and weight gain, and it’s diagnosed with blood tests (TSH and free T4). Don’t stop or change any medication on your own: your doctor can judge whether one of them is playing a role.

What doesn’t have evidence

• Detoxes, cleanses and “resets.” The NCCIH, the NIH’s center for complementary health, cites a 2015 review that found no compelling research supporting these diets for weight management or removing toxins. Some include laxatives, which can cause diarrhea and dehydration. I also haven’t found studies supporting a break from treatment to “reset” its effect.
• Supplements. According to MedlinePlus, many weight-loss supplement claims aren’t true, the evidence for their ingredients is missing or very weak, and some have serious side effects. Talk to your doctor before taking any.
• Skipping meals or eating a lot less. I haven’t found data showing it helps you get past a plateau. The advisory warns that eating less on a GLP-1 already raises the risk of nutrient deficiencies and of losing muscle and bone.

If you notice the plateau pushing you to restrict more and more, to feel fear or guilt around food, or to make up for what you eat, reach out for help. Eating disorders are serious mental health conditions, and they’re treatable.

What your situation might mean

It isn’t a personal failure

A plateau is physiology, not a lack of willpower: your body defends its weight with mechanisms you don’t control. Comparing yourself with numbers on social media or with a trial average only adds pressure.

Weight isn’t the only measure of treatment, either: blood pressure, blood sugar, strength and sleep count too. If you’re worried about what happens if you stop, I walk through the data in what happens when you stop Ozempic, Wegovy or Zepbound.

Frequently asked questions

How long does a plateau last?

There’s no set length. In the trials, the plateau at the end isn’t a pause before losing again; it’s the new stable weight while treatment continues. In STEP 5, it held from week 68 to the end of the trial at week 104. According to the advisory, as long as treatment continues, the weight loss is maintained for at least 4 years in published studies.

Does a higher dose break a plateau?

There’s no general answer. The US Wegovy label allows 7.2 mg for some adults, under the conditions above. In STEP UP (Study 8 in the label), with 1,407 adults with obesity and without diabetes, the label reports weight changes of −18.8% on 7.2 mg and −15.5% on 2.4 mg at 72 weeks (difference −3.3 points; 95% CI −4.9 to −1.6). The 95% CI, or confidence interval, is the range where the true effect probably lies. But the dose was assigned from the start, and I haven’t found published trials that tested a higher dose in people who had already plateaued. Whether it makes sense in your case is your doctor’s call.

Is it normal to lose almost nothing the first month?

It’s common. Treatment starts on low doses that go up gradually to reduce digestive side effects. In Ard’s analysis, 9 in 10 people who hadn’t reached 5% by week 12 got there later.

Does a plateau mean the drug has stopped working?

Not necessarily: it may be what’s keeping the weight off. In SURMOUNT-4, people switched to placebo regained a good part of it. If your weight goes up, mention it to your doctor.

Should I eat less to get past a plateau?

That’s not the answer: on a GLP-1 you’re already eating little, and eating even less raises the risk of deficiencies and muscle loss. It makes more sense to look after protein, strength training and sleep, with help from a registered dietitian.

Does weighing myself every day help?

Tracking your weight is part of programs with evidence behind them, but the sources I cite don’t set a frequency. If weighing yourself every day stresses you out, do it less often or stop, and mention it to your doctor.